- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- LJN452
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Knoxville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Interventions
- LYS006, Tropifexor
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Coronado, California • Los Angeles, California • Miami Lakes, Florida + 5 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Part 1: LJN452, Part 1: Placebo, Part 2: LJN452 Dose level 1, Part 2: Placebo, Part 2: LJN452 Dose level 2
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 9
- States / cities
- Rialto, California • Miami, Florida • Atlanta, Georgia + 6 more
- Conditions
- Primary Bile Acid Diarrhea
- Interventions
- LJN452, Placebo to LJN452
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non Alcoholic Steatohepatitis (NASH)
- Interventions
- Tropifexor, Licogliflozin, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 28
- States / cities
- Dothan, Alabama • Coronado, California • Los Angeles, California + 23 more
- Conditions
- Liver Disease
- Interventions
- triopifexor, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 10
- States / cities
- Madison, Alabama • Coronado, California • Miami, Florida + 7 more
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Tropifexor (LJN452), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 31
- States / cities
- Madison, Alabama • North Little Rock, Arkansas • Coronado, California + 28 more
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Tropifexor (LJN452), Cenicriviroc (CVC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 27
- States / cities
- Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more